Abstract

Volume.120 Number.5

Original article : Clinical science

Long-term Outcomes in Eyes Receiving of Bevacizumab Early in the Course of Branch Retinal Vein Occlusion
Masanori Setta1,3, Shiro Ozaki2, Akio Tabuchi3
1 Department of Ophthalmology, Ogaki Municipal Hospital
2 Ozaki Eye Clinic
3 Kawasaki University of Medical Welfare

Purpose: To evaluate the effects of intravitreal bevacizumab (IVB) injections early in the course of branch retinal vein occlusion (BRVO).
Patients and Methods: We conducted a retrospective review of 30 patients (30 eyes) with macular edema (ME) secondary to BRVO. The mean duration from the onset to the first IVB injection was 5 weeks. The mean observation period was 30 months. All patients were followed monthly, with administration of additional IVB injections if there was persistent or recurrent ME within 6 months after the first injection. The main outcome parameter was best-corrected visual acuity (BCVA) at 12 and 24 months. Rescue therapy including laser photocoagulation was done as needed.
Result: Mean BCVA improved significantly from logMAR 0.59±0.24 at baseline to 0.04±0.15 (p<0.001) at 12 month, 0.06±0.19 (p<0.001) at 24 month.
Conclusion: IVB injections given shortly after onset of branch retinal vein occlusion may result in a significant increase in vision in some patients.
Nippon Ganka Gakkai Zasshi (J Jpn Ophthalmol Soc) 120: 396-402, 2016.

Key words
Branch retinal vein occlusion, Early injection, Macular edema, Long-term, Bevacizumab
Reprint requests to
Shiro Ozaki, M.D. Ozaki Eye Clinic. 175-1 Yataka-cho, Nagahama-shi, Shiga-ken 526-0034, Japan